uniQure (NASDAQ:QURE) Shares Up 7.6%

Shares of uniQure (NASDAQ:QURE) shot up 7.6% during mid-day trading on Monday . The company traded as high as $39.43 and last traded at $38.75. 992,565 shares traded hands during trading, an increase of 132% from the average session volume of 428,491 shares. The stock had previously closed at $36.00.

A number of brokerages have issued reports on QURE. Royal Bank of Canada upped their price objective on uniQure from $53.00 to $61.00 and gave the company an “outperform” rating in a research report on Tuesday, December 22nd. HC Wainwright increased their price target on uniQure from $80.00 to $85.00 and gave the stock a “buy” rating in a report on Monday, December 21st. Credit Suisse Group increased their price target on uniQure from $76.00 to $78.00 and gave the stock an “outperform” rating in a report on Friday, November 20th. Jefferies Financial Group increased their price target on uniQure from $55.00 to $62.00 and gave the stock a “buy” rating in a report on Wednesday, December 9th. Finally, Berenberg Bank initiated coverage on uniQure in a report on Wednesday, November 11th. They issued a “buy” rating and a $59.00 price target on the stock. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $65.86.

The company has a market cap of $1.72 billion, a P/E ratio of -10.28 and a beta of 1.19. The firm has a 50 day moving average of $37.77 and a 200-day moving average of $40.51. The company has a quick ratio of 8.62, a current ratio of 8.62 and a debt-to-equity ratio of 0.16.

In other uniQure news, CAO Christian Klemt sold 952 shares of the stock in a transaction on Tuesday, January 26th. The stock was sold at an average price of $39.00, for a total transaction of $37,128.00. Following the sale, the chief accounting officer now owns 56,066 shares of the company’s stock, valued at approximately $2,186,574. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Matthew C. Kapusta sold 10,313 shares of the stock in a transaction on Wednesday, November 18th. The shares were sold at an average price of $43.69, for a total value of $450,574.97. Following the sale, the chief executive officer now directly owns 283,780 shares in the company, valued at approximately $12,398,348.20. The disclosure for this sale can be found here. In the last three months, insiders sold 56,582 shares of company stock worth $2,298,109. 2.79% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Sei Investments Co. boosted its position in uniQure by 2.3% during the 3rd quarter. Sei Investments Co. now owns 19,371 shares of the biotechnology company’s stock valued at $715,000 after acquiring an additional 437 shares in the last quarter. Capital Asset Advisory Services LLC boosted its position in uniQure by 11.9% during the 3rd quarter. Capital Asset Advisory Services LLC now owns 9,259 shares of the biotechnology company’s stock valued at $341,000 after acquiring an additional 984 shares in the last quarter. Banque Cantonale Vaudoise boosted its position in uniQure by 10.6% during the 3rd quarter. Banque Cantonale Vaudoise now owns 11,680 shares of the biotechnology company’s stock valued at $430,000 after acquiring an additional 1,121 shares in the last quarter. Pacer Advisors Inc. bought a new stake in uniQure during the 4th quarter valued at $75,000. Finally, California Public Employees Retirement System boosted its position in uniQure by 2.5% during the 3rd quarter. California Public Employees Retirement System now owns 85,295 shares of the biotechnology company’s stock valued at $3,141,000 after acquiring an additional 2,100 shares in the last quarter. 78.34% of the stock is currently owned by institutional investors and hedge funds.

About uniQure (NASDAQ:QURE)

uniQure N.V., a gene therapy company, engages in the development and commercialization of treatments for patients suffering from genetic and other diseases in the Netherlands. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B.

Read More: What are Institutional Investors?

Receive News & Ratings for uniQure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure and related companies with MarketBeat.com's FREE daily email newsletter.

Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit